# Non-interventional post-authorization study on effectiveness of reversal of local anaesthesia and on the occurrence of local reactions and cardiovascular adverse events in patients treated with OraVerse® versus patients not treated with OraVerse® (control group) in Germany (ORAPAES)

**First published:** 04/06/2013

**Last updated:** 25/06/2024

Study Finalised

## Administrative details

**EU PAS number**

EUPAS4062

**Study ID**

33005

**DARWIN EU® study**

No

**Study countries**

Germany

**Study description**

Non-interventional post-authorization study on effectiveness of reversal of local anaesthesia and on the occurrence of local reactions and cardiovascular adverse events in patients treated with OraVerse® versus patients not treated with OraVerse® (control group) in Germany

**Study status**

Finalised

# Research institutions and networks

## Institutions

### Sanofi

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

### Multiple centres: 12 centres are involved in the study

## Contact details

**Study institution contact**

Marie-Laure Kürzinger marie-laure.kurzinger@sanofi.com

Study contact

marie-laure.kurzinger@sanofi.com

**Primary lead investigator**

Kürzinger Marie-Laure Niedeggen Gabriele

Primary lead investigator

## Study timelines

**Date when funding contract was signed**

Planned: 31/12/2012

Actual: 31/12/2012

---

**Study start date**

Planned: 15/06/2013

Actual: 15/06/2013

---

**Data analysis start date**

Planned: 15/07/2014

Actual: 05/01/2015

---

**Date of final study report**

Planned: 15/06/2015

Actual: 30/06/2015

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Sanofi

## Regulatory

**Was the study required by a regulatory body?**

Yes

---

**Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

# Methodological aspects

## Study type

## Study type list

**Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness
Effectiveness study (incl. comparative)

**Data collection methods:**

Primary data collection

---

**Main study objective:**

-To compare time to recovery of normal sensation in the lip/tongue among patients treated with OraVerse® and not treated with OraVerse® (control group) after local anaesthetic procedures in routine clinical practice
-To compare time to recovery of normal function (eating, drinking and speaking) among patients treated with OraVerse® and not treated with OraVerse® (control group) after local anaesthetic procedures in routine clinical practice

## Study Design

**Non-interventional study design**

Cohort
Other

---

**Non-interventional study design, other**

Prospective, post-authorization study

## Study drug and medical condition

**Medicinal product name, other**

OraVerse

---

**Medical condition to be studied**

Cardiovascular disorder

# Population studied

**Short description of the study population**

Patients treated with OraVerse® and not treated with OraVerse® (control group) after local anaesthetic procedures in routine clinical practice.

Patients eligible for ORAPAES were those
1. who underwent local anesthesia by intraoral, submucosal injection of a local anesthetic containing a catecholamine vasoconstrictor, such as epinephrine (adrenaline) (dilution 1:100,000 or 1:200,000), after a routine dental procedure such as teeth cleaning, calculus removal, scaling and root planing, and restoration
preparation including crown preparation;
2. Who were at least 6 years old and weighed at least 15 kilograms (33.1 pounds);
3. For whom the dentist had made a decision to administer PM independent of the participation in the study;
4. who had signed an informed consent form

Patients eligible for ORANIS were patients
1. who received local anesthesia by intraoral submucosal injection of a local anesthetic solution containing a catecholamine vasoconstrictor, such as epinephrine
(dilution 1:100,000 or 1:200,000), after a routine dental procedure (teeth cleaning, scaling and root planing, restoration preparation, or preparation for crowns);

2. who were at least 18 years old; -those for whom the dentist had made a decision to administer PM independent of this documentation;
3. who had signed an informed consent, and were included consecutively, if eligible.

---

**Age groups**

- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

**Estimated number of subjects**

672

## Study design details

**Outcomes**

•Primary outcomes: Effectiveness. The primary outcomes will be the sensory and functional assessment measured by the patient the day of OraVerse® administration and collected the day after OraVerse® administration. •the patient reported time to recovery to normal:•sensation of upper lip, lower lip and tongue•functionality (speaking, drinking, eating),
•Secondary outcomes: Safety. The secondary outcomes of the study will be the frequency of local reactions (post-procedural pain, injection site pain, injection site reaction) and cardiovascular acute events (bradycardia, tachycardia, hypertension, hypotension, cardiac arrhythmia) which will be collected by the

dentist prior to discharge and during a phone call to the patient the day following the dental procedure.

**Data analysis plan**

•Primary objective: estimated median and corresponding 95% confidence interval of the time to recovery of normal sensation of the lip and tongue and of the time to recovery of functionality for each group (OraVerse® and control) will be calculated using the Kaplan-Meier method. (Stratified) log-rank-tests will be used to compare the survival curves of the 2 treatment groups. A Cox model with treatment group and potential confounders will be used to estimate the hazard ratio (HR) of outcome of interest using the control group as reference.
•Secondary objective: estimated frequency and corresponding 95% confidence interval of local reactions, cardiovascular events and cardiovascular events leading to healthcare consultation will be described for each group (OraVerse® and control). Logistic regression model will be used to estimate odds ratios (OR) to compare the frequency of local reactions between treatments groups after adjustment on potential confounders.

## Documents

**Study results**

JADA_Daublaender et al._ORAPAES_ORANIS.pdf (396.79 KB)

**Study publications**

Daubländer M, Liebaug F, Niedeggen G, Theobald K, Kürzinger ML. Effectiveness a...

# Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

**Data sources (types)**

Other

**Data sources (types), other**

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

# Data characterisation

**Data characterisation conducted**

No